SWOG clinical trial number
SWOG-9013 (INT-0113) (RTOG-89-11)

A Prospective Randomized Comparison of Combined Modality Therapy for Carcinoma of the Esophagus: Chemotherapy Plus Surgery versus Surgery Alone for Patients with Local Regional Disease

Closed
Phase
Published
Abbreviated Title
A Prospective Randomized Comparison of Combined Modality Therapy for Carcinoma of the Esophagus: Chemotherapy Plus Surgery versus Surgery Alone for Patients with Local Regional Disease
Activated
06/01/1990
Closed
12/31/1995

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

1998

Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer

DP Kelsen;R Ginsberg;TF Pajak;DG Sheahan;L Gunderson;J Mortimer;N Estes;DG Haller;J Ajani;W Kocha;BD Minsky;JA Roth New England Journal of Medicine 339(27):1979-1984

1997

Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: A preliminary report of intergroup study 113 (RTOG 89-11).

DP Kelsen;R Ginsberg;C Qian;L Gunderson;J Mortimer;N Estes;D Hailer;J Ajani;W Kocha;J Roth;B Minsky Proc of the American Society of Clinical Oncology 16:276a(#982)

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase